Des Moines, IA—In a randomized double-blind, placebo-controlled clinical trial on Kemin BetaVia Complete, a strain of Euglena gracilis, people using BetaVia Complete had 70% fewer upper respiratory tract infection (URTI) symptoms, nearly four fewer sick days and 10 fewer URTI symptom days over a 90-day period, according to a press release. The release states that BetaVia Complete supports immune health by priming key immune cells, providing nutritional support, and promoting cell signaling.
The study participants self-reported information based off of the Wisconsin Upper Respiratory Symptoms Survey (WURSS), which measures symptoms, their severity, and the functional impact they have with URTIs.
“This study builds upon the body of evidence for BetaVia Complete and further supports the efficacy of 1,3 beta glucan as an immunomodulator with the capacity to modify the function of the immune system,” said Kelli Herrlinger, director of clinical research at Kemin Human Nutrition and Health. “These results confirm that BetaVia Complete would be a great fit for consumer products formulated to support immune health.”
The release states that BetaVia Complete is a proprietary, nutrient-rich algae containing more than 50% 1,3 beta glucan. It is grown in a fermentation process patented by Kemin.
More information on BetaVia Complete can be found here.